BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 21775337)

  • 1. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
    Walraven CJ; North MS; Marr-Lyon L; Deming P; Sakoulas G; Mercier RC
    J Antimicrob Chemother; 2011 Oct; 66(10):2386-92. PubMed ID: 21775337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes and costs associated with a history of vancomycin exposure in patients with MRSA-related complicated bacteremia and infective endocarditis.
    Brown J; Brown KA; Forrest A
    Clin Ther; 2011 Oct; 33(10):1475-82. PubMed ID: 21925733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin.
    Yoon YK; Kim JY; Park DW; Sohn JW; Kim MJ
    J Antimicrob Chemother; 2010 May; 65(5):1015-8. PubMed ID: 20200036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of teicoplanin MICs on treatment outcomes among patients with teicoplanin-treated methicillin-resistant Staphylococcus aureus bacteraemia: a hospital-based retrospective study.
    Chang HJ; Hsu PC; Yang CC; Siu LK; Kuo AJ; Chia JH; Wu TL; Huang CT; Lee MH
    J Antimicrob Chemother; 2012 Mar; 67(3):736-41. PubMed ID: 22169187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of clinical and microbiological treatment failure in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: a retrospective cohort study in a region with low MRSA prevalence.
    Forstner C; Dungl C; Tobudic S; Mitteregger D; Lagler H; Burgmann H
    Clin Microbiol Infect; 2013 Jul; 19(7):E291-7. PubMed ID: 23490021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a clinical association of vancomycin MIC creep, agr group II locus, and treatment failure in MRSA bacteremia?
    de Sanctis JT; Swami A; Sawarynski K; Gerasymchuk L; Powell K; Robinson-Dunn B; Carpenter CF; Sims MD
    Diagn Mol Pathol; 2011 Sep; 20(3):184-8. PubMed ID: 21817905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
    J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: a retrospective cohort study.
    Goldberg E; Paul M; Talker O; Samra Z; Raskin M; Hazzan R; Leibovici L; Bishara J
    J Antimicrob Chemother; 2010 Aug; 65(8):1779-83. PubMed ID: 20507860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for mortality in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia in a tertiary care hospital in Taiwan.
    Lin SH; Liao WH; Lai CC; Liao CH; Tan CK; Wang CY; Huang YT; Hsueh PR
    J Antimicrob Chemother; 2010 Aug; 65(8):1792-8. PubMed ID: 20511366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia.
    Wi YM; Kim JM; Joo EJ; Ha YE; Kang CI; Ko KS; Chung DR; Song JH; Peck KR
    Int J Antimicrob Agents; 2012 Aug; 40(2):108-13. PubMed ID: 22633565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.
    Kullar R; Davis SL; Levine DP; Rybak MJ
    Clin Infect Dis; 2011 Apr; 52(8):975-81. PubMed ID: 21460309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
    Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of source of infection and vancomycin AUC0-24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Ghosh N; Chavada R; Maley M; van Hal SJ
    Clin Microbiol Infect; 2014 Dec; 20(12):O1098-105. PubMed ID: 24890030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vancomycin MICs do not predict the outcome of methicillin-resistant Staphylococcus aureus bloodstream infections in correctly treated patients.
    Rojas L; Bunsow E; Muñoz P; Cercenado E; Rodríguez-Créixems M; Bouza E
    J Antimicrob Chemother; 2012 Jul; 67(7):1760-8. PubMed ID: 22556382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
    Song KH; Kim HB; Kim HS; Lee MJ; Jung Y; Kim G; Hwang JH; Kim NH; Kim M; Kim CJ; Choe PG; Chung JY; Park WB; Kim ES; Park KU; Kim NJ; Kim EC; Oh MD
    Int J Antimicrob Agents; 2015 Dec; 46(6):689-95. PubMed ID: 26555059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Method-specific performance of vancomycin MIC susceptibility tests in predicting mortality of patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Chen SY; Liao CH; Wang JL; Chiang WC; Lai MS; Chie WC; Chang SC; Hsueh PR
    J Antimicrob Chemother; 2014 Jan; 69(1):211-8. PubMed ID: 23997017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy.
    Ho TT; Cadena J; Childs LM; Gonzalez-Velez M; Lewis JS
    J Antimicrob Chemother; 2012 May; 67(5):1267-70. PubMed ID: 22311935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin .
    Lodise TP; Drusano GL; Lazariu V; El-Fawal N; Evans A; Graffunder E; Stellrecht K; Mendes RE; Jones RN; Cosler L; McNutt LA
    J Antimicrob Chemother; 2014 Sep; 69(9):2547-55. PubMed ID: 24840624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methicillin-resistant Staphylococcus aureus bacteremia in hemodialysis and nondialysis patients.
    Kan LP; Lin JC; Chiu SK; Yeh YC; Lin TY; Yang YS; Wang YC; Wang NC; Yeh KM; Chang FY
    J Microbiol Immunol Infect; 2014 Feb; 47(1):15-22. PubMed ID: 23040238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections.
    Hermsen ED; Hanson M; Sankaranarayanan J; Stoner JA; Florescu MC; Rupp ME
    Expert Opin Drug Saf; 2010 Jan; 9(1):9-14. PubMed ID: 20021290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.